[The use of propes in the combined treatment of malignant lymphomas].
Results are submitted of use of propes during different phases of treatment in 36 patients with malignant lymphomas. The above drug is associated with no complications or side effects, inhibits the development of the tumor process. The employment of propes permits enhancing both natural resistance of the organism and its killer activity. It is an effective aid to cytostatic therapy as a way for prophylaxis of hypoplasia of haemopoiesis which can be successfully used in other malignant tumors.
Kindzel'skiĭ
L P
LP
Gubareva
A A
AA
Tomilina
N A
NA
Sivkovich
S A
SA
Ponomareva
O V
OV
Naĭshtetik
V Ia
VIa
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004341:Drug Evaluation; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy*; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction
D000276:Adjuvants, Immunologic
Primenenie propesa v kompleksnom lechenii zlokachestvennykh limfom.